ArticleIEEE International Conference on Bioinformatics and Biomedicine workshops. IEEE International Conference on Bioinformatics and Biomedicine2023
Prediction of Drug Targets based on In Vitro Activity Profiles Toward Drug Repurposing for Rare Diseases.
Article in IEEE International Conference on Bioinformatics and Biomedicine workshops. IEEE International Conference on Bioinformatics and Biomedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Over 300 million people are suffering from rare diseases, most of which have limited treatment options. Therefore, discovering new treatments for rare diseases is imperative. Drug repurposing, which identifies new uses for approved drugs, is considered one of the viable and risk-managed strategies for disease treatments. To promote the drug repurposing process, we introduced a prediction model to uncover novel relationships between gene targets and chemical compounds. In our previous study, we identified enriched genes for compounds from the Toxicology in the 21st Century program (Tox21) 10K library, to extend that study for enriched gene target prediction, we developed machine learning (ML) models including Support Vector Machine; K-Nearest Neighbors; Random Forest; and extreme gradient boosting (XGBoost), by using Tox21 bioassay screening data. All four models perform well with f1_score over 0.7, and XGBoost has the best performance with four different multi-label prediction embedding algorithms, including Binary Relevance; Label Powerset; Classifier Chain; Multi-Output Classifier. Our study explored a reliable method to predict potential gene targets from in vitro activity profile data toward drug repurposing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.